Corvus Pharmaceuticals $34 million stock offering
We advised the underwriters on the equity offering
2/17/2021

Davis Polk advised the joint book-running managers in connection with a $34 million SEC-registered common stock offering by Corvus Pharmaceuticals, Inc., which included shares sold pursuant to a partial exercise of the underwriters’ option to purchase additional shares. The common stock is listed on the Nasdaq Global Market under the symbol “CRVS.”

Corvus is a clinical stage, immunology focused biopharmaceutical company focusing its efforts on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Benson Richards and Alex DeGroat. The intellectual property and technology transactions team included partner David R. Bauer and associate Jay Frankel. The tax team included counsel Kiara L. Rankin and associate Ben Levenback. Associate Brantley Hawkins provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.